{"id":"W2018929154","doi":"10.1200/jco.2007.12.1939","title":"Phase II Clinical Trial of Bevacizumab and Low-Dose Metronomic Oral Cyclophosphamide in Recurrent Ovarian Cancer: A Trial of the California, Chicago, and Princess Margaret Hospital Phase II Consortia","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":549,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute","keywords":"Medicine; Bevacizumab; Internal medicine; Cyclophosphamide; Vascular endothelial growth factor; Regimen; Adverse effect; Ovarian cancer; Clinical endpoint; Oncology; Chemotherapy; Gastroenterology; Phases of clinical research; Cancer; Surgery; Clinical trial","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00256581,0.001578489,0.001634677,0.000452758,0.0005069333,0.001277752,0.00100558,0.002367568,0.005214468],"category_scores_gemma":[0.001648982,0.0006040435,0.001258094,0.0004382156,0.0008695286,0.0006605869,0.0004406449,0.003081204,0.0006744321],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009688691,"about_ca_system_score_gemma":0.002284821,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001208767,"about_ca_topic_score_gemma":0.002866525,"domain_scores_codex":[0.9994107,0.00034572,0.00002402674,0.00008099543,0.00005323413,0.00008524371],"domain_scores_gemma":[0.9988165,0.0002217584,0.000249475,0.00006423676,0.00008001732,0.0005680548],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.8731094,0.03771213,0.003849553,0.0009758689,0.001076481,0.0001904285,0.0001869078,0.001333755,0.01317916,0.0005676818,0.01034557,0.05747303],"study_design_scores_gemma":[0.9359291,0.05912146,0.002034998,0.00003354675,0.0001342186,0.00006877921,0.00001468871,0.0007100849,0.000440429,0.0001012929,0.001399347,0.00001203577],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9748239,0.005945967,0.001052737,0.002119604,0.0006192744,0.009662576,0.001741771,0.0001808358,0.003853433],"genre_scores_gemma":[0.9536477,0.004218332,0.005128945,0.003934984,0.000721837,0.01869674,0.005074279,0.00006101365,0.008516036],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005214468,"threshold_uncertainty_score":0.01744419,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.08053328566653827,"score_gpt":0.4726185715195743,"score_spread":0.392085285853036,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}